ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 445,69
2,24%
Dow Jones
42 706,56
-0,06%
DAX
20 216,19
1,54%
Brent Oil
75,875
-0,32%
Bitcoin
101 906,98
-0,37%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. IGM Biosciences Inc (IGMS) Cours

IGM Biosciences Inc

IGM Biosciences Inc (IGMS)

NASDAQ
6,50
-0,06
(-0,91%)
Fermé 07 Janvier 10:00PM
Retardé de 15 minutes
6,50
0,02
(0,31%)
Après les heures de négociation: 1:50AM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
6,50
Prix Achat
6,20
Prix Vente
6,52
Volume échangé
197 926
6,37 Fourchette du Jour 6,8676
5,79 Plage de 52 semaines 22,50
Cap du marché
386,517M
Clôture Veille
6,56
Ouverture
6,76
Dernière Transaction
1
@
6.3
Dernière heure de transaction
Volume financier
US$ 1 293 264
VWAP
6,5341
Volume moyen (3 m)
232 968
Actions en circulation
59 464 181
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-1,56
Bénéfice par action (BPA)
-4,14
Chiffre d'affairess
2,13M
Bénéfice net
-246,42M

À propos de IGM Biosciences Inc

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking ago... IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.igmbio.com
Siège social
Dover, Delaware, USA
Fondé
-
IGM Biosciences Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker IGMS. Le dernier cours de clôture d'IGM Biosciences était de US$6,56. Au cours de la dernière année, les actions de IGM Biosciences ont été négociées dans une fourchette de prix de US$ 5,79 à US$ 22,50.

IGM Biosciences compte actuellement 59 464 181 actions en circulation. La capitalisation boursière d'IGM Biosciences est de US$390,09 million. IGM Biosciences a un ratio cours/bénéfice (ratio PE) de -1.56.

IGMS Dernières nouvelles

Plus de nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

04 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

03 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

03 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

03 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

19 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

19 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

19 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

19 Décembre 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

16 Décembre 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

16 Décembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.172.685624012646.337.025.793240716.23123467CS
4-3.81-36.954413191110.3110.85.792432247.04037289CS
12-8.75-57.377049180315.2520.355.7923296810.96992866CS
260.081.2461059196.4222.55.7928914512.10669811CS
52-3.65-35.96059113310.1522.55.7929681411.19220099CS
156-19.39-74.893781382825.8935.983.8135457616.48634939CS
260-27.3-80.769230769233.81333.8128397729.54487015CS

IGMS - Frequently Asked Questions (FAQ)

What is the current IGM Biosciences share price?
The current share price of IGM Biosciences is US$ 6,50
How many IGM Biosciences shares are in issue?
IGM Biosciences has 59 464 181 shares in issue
What is the market cap of IGM Biosciences?
The market capitalisation of IGM Biosciences is USD 390,09M
What is the 1 year trading range for IGM Biosciences share price?
IGM Biosciences has traded in the range of US$ 5,79 to US$ 22,50 during the past year
What is the PE ratio of IGM Biosciences?
The price to earnings ratio of IGM Biosciences is -1,56
What is the cash to sales ratio of IGM Biosciences?
The cash to sales ratio of IGM Biosciences is 181,01
What is the reporting currency for IGM Biosciences?
IGM Biosciences reports financial results in USD
What is the latest annual turnover for IGM Biosciences?
The latest annual turnover of IGM Biosciences is USD 2,13M
What is the latest annual profit for IGM Biosciences?
The latest annual profit of IGM Biosciences is USD -246,42M
What is the registered address of IGM Biosciences?
The registered address for IGM Biosciences is CORPORATION TRUST CENTER, 1209 ORANGE ST, DOVER, DELAWARE, 19901
What is the IGM Biosciences website address?
The website address for IGM Biosciences is www.igmbio.com
Which industry sector does IGM Biosciences operate in?
IGM Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BOXLBoxlight Corporation
US$ 1,645
(257,61%)
240,3M
SPRCSciSparc Ltd
US$ 1,06
(100,80%)
189,11M
XTIAXTI Aerospace Inc
US$ 0,08261
(99,54%)
1,55B
DHAIDIH Holdings US Inc
US$ 2,8602
(82,18%)
4,62M
NXPLNextPlat Corporation
US$ 1,73
(61,68%)
12,6M
RGFReal Good Food Company Inc
US$ 1,31
(-63,49%)
1,47M
LUNALuna Innovations Incorporated
US$ 0,8744
(-57,35%)
12,29M
GCTKGlucoTrack Inc
US$ 0,1594
(-45,65%)
35,68M
ACONAclarion Inc
US$ 0,1699
(-43,06%)
35,02M
BLRXBioLineRx Ltd
US$ 0,1621
(-40,80%)
44,6M
XTIAXTI Aerospace Inc
US$ 0,08261
(99,54%)
1,55B
NVDANVIDIA Corporation
US$ 149,43
(3,43%)
264,21M
CNSPCNS Pharmaceuticals Inc
US$ 0,11987
(-2,54%)
246,57M
BOXLBoxlight Corporation
US$ 1,645
(257,61%)
240,3M
SPRCSciSparc Ltd
US$ 1,06
(100,80%)
190,36M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
IGMS
IGM Biosciences
TG
A28R19
Fresenius
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés